{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:00:46Z","timestamp":1791669646133,"version":"4.3.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate long-term safety and effectiveness of lurasidone in children and adolescents with bipolar depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Participants, ages 10\u201317 years, with bipolar depression, who completed 6 weeks of double-blind (DB) treatment with lurasidone or placebo were enrolled in a 2-year, open-label (OL) extension study of lurasidone (20\u201380\u2009mg\/d). The primary effectiveness measure was the Children's Depression Rating Scale, Revised (CDRS-R).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 306 participants entered the 2-year extension study; 195 (63.7%) completed 52 weeks, and 168 (54.9%) completed 104 weeks of treatment. For all participants entering the extension study, mean change in CDRS from OL baseline was \u221213.4 at week 52, and \u221216.4 at week 104 (\u221211.3 at last observation carried forward [LOCF]-endpoint). Overall, 31 participants (10.1%) discontinued due to an adverse event (AE); the three most common AEs were headache (23.9%), nausea (16.4%), and somnolence (9.8%). OL treatment with lurasidone was associated with few effects on metabolic parameters or prolactin. Mean change from DB baseline in weight was +4.25\u2009kg at week 52 (vs. an expected weight gain of +3.76\u2009kg), and +6.75\u2009kg at week 104 (vs. an expected weight gain of +6.67\u2009kg), based on the sex- and age-matched United States Center for Disease Control normative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>For youth with bipolar depression, up to 2 years of treatment with lurasidone was generally well tolerated, safe, and effective with relatively low rates of discontinuation due to AEs, minimal effects on weight, metabolic parameters or prolactin, and continued improvement in depressive symptoms.<\/jats:p>\n                    <jats:p>Clinical Trial Registration number: NCT01914393.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2021.0040","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T16:02:24Z","timestamp":1627574544000},"page":"494-503","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1837-4126","authenticated-orcid":false,"given":"Melissa P.","family":"DelBello","sequence":"first","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tocco","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals, Inc., Fort Lee, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Deng","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals, Inc., Fort Lee, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goldman","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 5th ed. Washington DC: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32835a2acf"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579406060500"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13121577"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12133"},{"key":"e_1_3_4_7_1","first-page":"211","article-title":"Effects of lurasidone in behavioral models of depression","volume":"70","author":"Cates LN","year":"2013","unstructured":"Cates LN, , Roberts AJ, , Huitron-Resendiz S, , Hedlund PB: Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology, 70:211\u2013217, 2013.","journal-title":"Role of the 5-HT7 receptor subtype. Neuropharmacology"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835281ef"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001893"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00728.x"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2017.10.006"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0010"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.12.012"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000198590.38325.81"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0105"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0189"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12921"},{"key":"e_1_3_4_18_1","first-page":"965","article-title":"Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease","volume":"132","author":"Goldstein BI","year":"2015","unstructured":"Goldstein BI, , Carnethon MR, , Matthews KA, , McIntyre RS, , Miller GE, , Raghuveer G, , Stoney CM, , Wasiak H, , McCrindle BW; American Heart Association Atherosclerosis; Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young: Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease. A scientific statement from the American Heart Association. Circulation, 132:965\u2013986, 2015.","journal-title":"A scientific statement from the American Heart Association. Circulation"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.03.016"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2017.11.006"},{"key":"e_1_3_4_22_1","first-page":"1","article-title":"The UKU side effect rating scale","volume":"334","author":"Lingjaerde O","year":"1987","unstructured":"Lingjaerde O, , Ahlfors UG, , Bech P, , Dencker SJ, , Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl, 334:1\u2013100, 1987.","journal-title":"A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.114.048793"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985"},{"key":"e_1_3_4_26_1","first-page":"95","article-title":"Effectiveness of lurasidone vs","volume":"147","author":"Loebel A","year":"2013","unstructured":"Loebel A, , Cucchiaro J, , Xu J, , Sarma K, , Pikalov A, , Kane JM: Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr Res, 147:95\u2013102, 2013.","journal-title":"quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr Res"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.05.059"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/11204430-000000000-00000"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.45"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00006"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00686.x"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.01.022"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113274"},{"key":"e_1_3_4_35_1","volume-title":"Manual","author":"Poznanski EO","year":"1996","unstructured":"Poznanski EO, , Mokros HB: Children's Depression Rating Scale\u2013Revised: Manual. Los Angeles: Western Psychological Services; 1996."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.09.017"},{"key":"e_1_3_4_37_1","first-page":"S215","article-title":"Results from an open-label extension phase [abstract no","volume":"2","author":"Robertson-Plouch C","year":"2007","unstructured":"Robertson-Plouch C, , Kryzhanovskaya L, , Schulz C. Olanzapine efficacy and tolerability in adolescents with schizophrenia: Results from an open-label extension phase [abstract no. 454]. Pharmacoepidemiol Drug Saf 16 Suppl. 2:S215, 2007.","journal-title":"454]. Pharmacoepidemiol Drug Saf 16 Suppl"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_4_39_1","first-page":"127","article-title":"Neuropsychological profiles of major depressive disorder and bipolar disorder during euthymia","volume":"248","author":"Szmulewicz AG","year":"2017","unstructured":"Szmulewicz AG, , Valerio MP, , Smith JM, , Samam\u00e9 C, , Martino DJ, , Strejilevich SA: Neuropsychological profiles of major depressive disorder and bipolar disorder during euthymia. A systematic literature review of comparative studies. Psychiatry Res, 248:127\u2013133, 2017.","journal-title":"A systematic literature review of comparative studies. Psychiatry Res"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115620460"},{"issue":"2","key":"e_1_3_4_41_1","first-page":"S215","article-title":"Olanzapine in the treatment of adolescents with bipolar mania; 26-week open-label extension [abstract no. 453]","volume":"16","author":"Tohen M","year":"2007","unstructured":"Tohen M, , Kryzhanovskaya L, , Carlson G. Olanzapine in the treatment of adolescents with bipolar mania; 26-week open-label extension [abstract no. 453]. Pharmacoepidemiol Drug Saf, 16 Suppl. 2:S215, 2007.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12180"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002373"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2021.0040","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:11Z","timestamp":1777388171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2021.0040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1089\/cap.2021.0040"],"URL":"https:\/\/doi.org\/10.1089\/cap.2021.0040","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}